Brainstorm Cell Therapeutics Inc.
corporate_fare Company Profile
Brainstorm Cell Therapeutics Inc. (OTC:BCLI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for BCLI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for BCLI spans 8-K, 10-Q, S-1, 10-K.
Recent high-impact activity:
- BrainStorm Q3 2026: $1.7M Quarterly Loss, Only $0.35M Cash Against $13.2M Current Liabilities
- BrainStorm 10-Q: Going Concern, Material Weakness, and New Litigation
- BrainStorm Reports Q2 Loss, $0.2M Cash; Prepares Phase 3b ALS Trial
- BrainStorm Names Former FDA Official Peter Pitts Executive Chairman; Chairman and CMO Depart
- Brainstorm Cell Therapeutics Appoints Former FDA Associate Commissioner to Board
Financial Snapshot
Short Interest & Short Volume
2.01 days to coverFINRA reported short interest of 60,573 shares in BCLI as of the October 30, 2026 settlement, a 77.0% increase from the prior period — about 2.0 days to cover at its recent average daily volume. On November 20, 2026, 17.2% of BCLI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.